Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2009 | Original Article

Effect of cyclosporin A administration on the biodistribution and multipinhole μSPECT imaging of [¹²³I]R91150 in rodent brain

Authors: P. Blanckaert, I. Burvenich, S. Staelens, S. De Bruyne, L. Moerman, L. Wyffels, F. De Vos

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2009

Abstract

Purpose

P-glycoprotein (Pgp) is an efflux protein found amongst other locations in the blood–brain barrier. It is important to investigate the effect of Pgp modulation on clinically used brain tracers, because brain uptake of the tracer can be altered by blocking of the Pgp efflux transporter. The function of Pgp can be blocked with cyclosporin A.

Methods

We investigated the effect of cyclosporin A administration on the biodistribution of [¹²³I]R91150 in rodents, and the effect of Pgp blocking on the quality of multipinhole μSPECT imaging with [¹²³I]R91150. The influence of increasing doses of cyclosporin A on the brain uptake of [¹²³I]R91150 was investigated in NMRI mice. A biodistribution study with [¹²³I]R91150 was performed in male Sprague-Dawley rats pretreated with cyclosporin A and not pretreated. Brain uptake of [¹²³I]R91150 after cyclosporin A injection was compared to the brain uptake in untreated animals, and a displacement study with ketanserin was performed in both groups. A multipinhole μSPECT brain imaging study was also performed using a Milabs U-SPECT-II camera in male Sprague-Dawley rats. To exclude the effect of possible metabolites, a metabolite study was also performed.

Results

At the highest cyclosporin A dose (50 mg/kg), a sevenfold increase in brain radioactivity concentration was observed in NMRI mice. Also, a dose-response relationship was established between the dose of cyclosporin A and the brain uptake of [¹²³I]R91150 in mice. Compared to the control group, a five-fold increase in [¹²³I]R91150 radioactivity concentration was observed in the brain of Sprague-Dawley rats after cyclosporin A treatment (50 mg/kg). Radioactivity concentration in the frontal cortex increased from 0.24±0.0092 to 1.58±0.097% injected dose per gram of tissue after treatment with cyclosporin A (at the 1-h time-point). Blood radioactivity concentrations did not increase to the same extent. The cortical activity was displaced by administration of ketanserin. A metabolite study confirmed that there was no increased metabolism of [¹²³I]R91150 due to cyclosporin A. The visual quality of multipinhole μSPECT images with [¹²³I]R91150 in Sprague-Dawley rats improved markedly after cyclosporin A pretreatment.

Conclusion

From the results obtained in the biodistribution studies, it can be concluded that [¹²³I]R91150 is a substrate for Pgp in rodents. A relationship between the administered dose of cyclosporin A and the increase in [¹²³I]R91150 brain radioactivity concentration was established. The overall quality of our multipinhole μSPECT images with [¹²³I]R91150 in rats improved markedly after pretreatment of the animals with cyclosporin A.

Heinrich T, Böttche H, Prücher H, Gottschlich R, Ackermann K-A, van Amsterdam C. 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-ht2A antagonists. Chem Med Chem 2006;1:245–55.PubMed

Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083–152.PubMedCrossRef

Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 2005;58:249–57.PubMedCrossRef

Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, et al. [C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci 1996;58:L187–92.CrossRef

Mathis CA, Mahmood K, Huang Y, Simpson NR, Gerdes JM, Price JC. Synthesis and preliminary in vivo evaluation of [C-11]MDL 100907: a potent and selective radioligand for the 5-HT2A receptor system. Med Chem Res 1996;6:1–10.

Catafau AM, Danus M, Bullich S, Llop J, Perich J, Cunningham VJ, et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: Part 1 – Pseudoequilibrium interval and quantification methods. J Nucl Med 2006;47:919–28.PubMed

Catafau AM, Danus M, Bullich S, Nucci G, Llop J, Abanades S, et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: part 2 – ketanserin displacement. J Nucl Med 2006;47:929–37.PubMed

Marner L, Knudsen GM, Madsen K, Haugbol S, Vogel A, Holm S, et al. Longitudinal assessment of cerebral 5-HT2A receptors in normal volunteers. An [18F]-altanserin PET study. Neuroimage 2006;31:T101.CrossRef

Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 2004;55:217–24.PubMedCrossRef

10.

Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, et al. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [F-18]altanserin and positron emission tomographic imaging. Psychiatry Res 1996;68:11–22.PubMedCrossRef

11.

Sheline YI, Mintun MA, Moerlein SM, Vlassenko AG, Xue F, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in medication naive major depression measured with [18F] altanserin positron emission tomography. Biol Psychiatry 2003;53:10S.

12.

de Vries EFJ, Kortekaas R, van Waarde A, Dijkstra D, Elsinga PH, Vaalburg W. Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET tracer for P-glycoprotein. J Nucl Med 2005;46:1384–92.PubMed

13.

Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 2007;48:81–7.PubMed

14.

Syvanen S, Blomquist G, Sprycha M, Hoglund AU, Roman M, Eriksson O, et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006;32:1134–41.PubMedCrossRef

15.

van Eerd JEM, De Geus-Oei LF, Oyen WJG, Corstens FHM, Boerman OC. Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. Eur J Nucl Med Mol Imaging 2006;33:1266–72.PubMedCrossRef

16.

Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385–427.PubMedCrossRef

17.

Hendrikse NH, Frans EJ, Van der Graaf WTA, Vaalburg W, De Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283–93.PubMedCrossRef

18.

Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003;307:262–7.PubMedCrossRef

19.

Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased Mdr-1/P-Glycoprotein expression after treatment of human colon-carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993;268:2946–52.PubMed

20.

van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 1996;88:994–9.PubMedCrossRef

21.

Liow JS, Lu SY, McCarron JA, Hong JS, Musachio JL, Pike VW, et al. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [C-11](R)-(-)-RWAY. Synapse 2007;61:96–105.PubMedCrossRef

22.

Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 2005;7:37–44.PubMedCrossRef

23.

Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998;124:1413–18.PubMedCrossRef

24.

Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [C-11]verapamil. J Pharmacol Exp Ther 2006;316:647–53.PubMedCrossRef

25.

Joseph B, Bhargava KK, Malhi H, Schilsky ML, Jain D, Palestro CJ, et al. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes. Eur J Nucl Med Mol Imaging 2003;30:1024–31.PubMedCrossRef

26.

Kiyono Y, Yamashita T, Doi H, Kuge Y, Katsura T, Inui KI, et al. Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging 2007;34:448–52.PubMedCrossRef

27.

Baeken C, D’haenen H, Flamen P, Mertens J, Terriere D, Chavatte K, et al. I-123-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med 1998;25:1617–22.PubMedCrossRef

28.

Mertens J, Terriere D, Sipido V, Gommeren W, Janssen PMF, Leysen JE. Radiosynthesis of a new radioiodinated ligand for serotonin-5Ht(2)-receptors, a promising tracer for gamma-emission tomography. J Labelled Compd Radiopharm 1994;34:795–806.CrossRef

29.

Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using C-11-verapamil. J Nucl Med 2006;47:1427–33.PubMed

30.

Katoh M, Suzuyama N, Takeuch T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 2006;95:2673–83.PubMedCrossRef

Title: Effect of cyclosporin A administration on the biodistribution and multipinhole μSPECT imaging of [123I]R91150 in rodent brain
Authors: P. Blanckaert
I. Burvenich
S. Staelens
S. De Bruyne
L. Moerman
L. Wyffels
F. De Vos
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0968-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of cyclosporin A administration on the biodistribution and multipinhole μSPECT imaging of [¹²³I]R91150 in rodent brain

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2009

Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET

Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study

Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study

Ich bin ein Molekularmediziner (how much CT and nuclear medicine in molecular CT?)

Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up

Metabolic–flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT